A Phase 4, Open-Label, Non-Randomized, Multicenter Study to Evaluate Safety and Efficacy of Intravenous Administration of OPTISON™ for Contrast- Enhanced Echocardiography in Pediatric Patients
Latest Information Update: 20 May 2025
At a glance
- Drugs Perflutren (Primary)
- Indications Left ventricular dysfunction
- Focus Diagnostic use
- Sponsors GE Healthcare
Most Recent Events
- 13 May 2025 According to a GE HealthCare media release, the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA).
- 08 Apr 2024 Results (n=37) assessing Efficacy of Intravenous Administration of Optison for Contrast-Enhanced Echocardiography in Pediatric Patients presented at the 73rd Annual Scientific Session of the American College of Cardiology
- 22 Jun 2023 Status changed from recruiting to completed.